Mykel Green

The Green Engineering Equity group focuses on developing biomaterial-based approaches to improve hematopoietic stem cell (HSC) transplantation, using sickle cell disease as a primary model system. We investigate how factors like pathology, sex, and age modify HSC function through engineered in vitro and in vivo models to inform our biomaterial design. By exploiting bone marrow physiology, our platforms aim to improve stem cell transplantation engraftment and recovery. Our ultimate goal is to develop more effective, cost-efficient procedures, creating equitable treatments for the various disorders reliant upon hematopoietic stem cell transplantation.

In tandem with our biomedical research, our educational initiatives integrate healthcare equity into engineering curricula to enhance student retention, success, and overall experience. By combining advanced technical education with an understanding of ethical and human-centered aspects of engineering, we foster a more inclusive and equitable learning environment. This approach ensures that students are not only technically proficient but also socially conscious, preparing them to tackle complex healthcare challenges and contribute meaningfully to health equity.